Investing

IPO News This Week: As August Heats Up, Offerings Cool Off

Thinkstock

Last week’s initial public offering (IPO) action saw four of five scheduled listings make their entry into the public markets. The four IPOs raised a total of $307 million in new capital, as three of the four priced below the midpoint of their expected ranges. The coming week includes two small offerings seeking a total of $58 million, one a first-timer and one a holdover from last week.

First a brief review of last week’s successful IPOs.

Amalgamated Bank (NASDAQ: AMAL) raised $104 million selling 6.7 million shares at $15.50, near the low-end of the expected range of $15 to $17. Shares dropped 3% on their first trading day but ended the week up 6%.

Spartan Energy Acquisition (NYSE: SPAQU), a blank-check company, raised $480 million selling 48 million units at $10. Units closed the week up 1%.

Pacific City Financial Corp. (NASDAQ: PCB) raised $48 million in a downsized offering of 2.4 million shares at $20, the low end of the expected range. Shares dropped 5% on the first day of trading and closed the week flat.

Mesa Air Group Inc. (NASDAQ: MESA) raised $116 million in a downsized offering of 9.6 million shares priced at $12, well below the expected range of $14 to $16. Shares dropped 2% on the Thursday IPO, and that’s how they closed the week.

Vaccinex Inc. (NASDAQ: VCNX) raised $40 million selling 3.33 million shares at $12, the low end of the expected range. Shares dropped 5% on the Thursday IPO and closed the week down 4%.

Through the week ending August 10, IPO ETF manager Renaissance Capital reported that 132 IPOs have priced in the U.S. so far this year, up about 44% year over year. Total proceeds raised through last week equaled $34.4 billion, up about 55% year over year.

For 2017, Renaissance Capital reported a total of 160 IPOs, up 52% year over year from 105 in 2016. Total 2017 proceeds amounted to $35.5 billion compared with a 2016 total of $18.8 billion. Renaissance Capital does not include “best efforts” or blank-check companies in its totals, nor does it include IPOs that raise less than $10 million.

Here are the two IPOs on this week’s agenda.

Bionano Genomics Inc., a life sciences instrumentation maker selling a proprietary system for next-generation genome analysis, delayed its IPO from last week. The company plans to offer 5.5 million shares in an expected price range of $5 to $6 to raise $30 million at a market cap of $85 million. Underwriters are Roth Capital and Maxim Group LLC. Shares are listed only as “week of” and will trade on the Nasdaq under the ticker symbol BNGO.

Aridis Pharmaceuticals is a late-stage biopharmaceutical firm developing immunotherapies for antibiotic-resistant infections. The company plans to offer 2 million shares in an expected price range of $13 to $15 to raise $28 million at a market cap of $111 million. Underwriters include Cantor Fitzgerald, Maxim Group LLC, Laidlaw & Co. (U.K.), Northland Securities, and The Seaport Group. Shares are expected to price Monday and begin trading Tuesday on the Nasdaq under the ticker symbol ARDS.

 

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.